Back to Journals » International Journal of Nanomedicine » Volume 12

Corrigendum

Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer [Corrigendum]

         

Authors Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie DH, Zhou M, Duan YR, Yin PH, Peng ZH

Received 31 March 2017

Accepted for publication 31 March 2017

Published 28 June 2017 Volume 2017:12 Pages 4661—4662

DOI https://doi.org/10.2147/IJN.S138486


Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie DH, Zhou M, Duan YR, Yin PH, Peng ZH. Int J Nanomedicine. 2014;9(1):4035–4041.

On page 4040, Figure 6C is incorrect.

Read the original article

Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer [Corrigendum]

Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie DH, Zhou M, Duan YR, Yin PH, Peng ZH. Int J Nanomedicine. 2014;9(1):4035–4041.

On page 4040, Figure 6C is incorrect. The correct figure is shown below.

Figure 6 Images of livers (upper images) and H&E staining in each group (lower images), 3 weeks after treatment.
Notes: The images of livers in each group indicated decreased metastatic lesion size and number in groups C, D, and E, compared with groups A and B, 3 weeks after treatment. Markedly inhibited colorectal cancer metastasis was shown in groups C, D, and E. The inhibitory effect on colorectal cancer metastasis of bufalin-loaded pluronic PEI nanocapsules exceeded that of bufalin administration alone. H&E staining gave similar results; liver structure damage caused by metastasis was lower in groups C, D, and E than in groups A and B. As shown, metastatic damage in groups A and B was more serious and more complete.
Abbreviations: PEI, polyetherimide; H&E, hematoxylin-eosin.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]